Trial Profile
A Phase I Study of TAK-659 and Paclitaxel in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Mivavotinib (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 24 Feb 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2019 Status changed from not yet recruiting to recruiting.